Paladin Labs Newswire

Paladin Labs Newswire

Comprehensive Real-Time News Feed for Paladin Labs.

Results 1 - 20 of 20 in Paladin Labs

  1. GUD Medison Taken at KnightRead the original story w/Photo

    9 hrs ago | Market Wire

    ... are intended for patients with rare and severe diseases. "Meir founded Medison the same year that I started Paladin Labs Inc. We embarked on the same strategy of representing innovative pharmaceuticals companies with products that touch the lives of ...

    Comment?

  2. New Market Report: Low Back Pain - Pipeline Review, H1 2015Read the original story w/Photo

    Monday Aug 24 | PR-inside.com

    ... S.A., MEDRx Co., Ltd., Merck & Co., Inc., Mesoblast Limited, Nektar Therapeutics, Pacira Pharmaceuticals, Inc., Paladin Labs Inc., Pfizer Inc., Stayble Therapeutics, Teikoku Pharma USA, Inc. About Global Markets Direct Global Markets Direct is a ...

    Comment?

  3. Low Back Pain - Pipeline Review, H1 2015; New Report LaunchedRead the original story w/Photo

    Jul 15, 2015 | SBWire

    ... S.A., MEDRx Co., Ltd., Merck & Co., Inc., Mesoblast Limited, Nektar Therapeutics, Pacira Pharmaceuticals, Inc., Paladin Labs Inc., Pfizer Inc., Stayble Therapeutics, Teikoku Pharma USA, Inc. For further information on this report, please visit- ...

    Comment?

  4. Antibe Therapeutics Inc. Announces Change In CFO Position And Granting Of Employee Stock OptionsRead the original story

    Jul 12, 2015 | BioSpace

    ... a member of Antibe's board of directors, brings a wealth of experience to the CFO role. She was the CFO of Paladin Labs Inc. for 13 years, responsible for leading the finance, operations, human resources, and investor-relations teams. Help employers ...

    Comment?

  5. Antibe Therapeutics Announces Change in CFO Position and Granting of Employee Stock OptionsRead the original story

    Jul 13, 2015 | Business Wire

    ... a member of Antibe's board of directors, brings a wealth of experience to the CFO role. She was the CFO of Paladin Labs Inc. for 13 years, responsible for leading the finance, operations, human resources, and investor-relations teams. During her ...

    Comment?

  6. New Study: Corporate Tax Rate Most Important Single Factor for InvestmentRead the original story w/Photo

    Jul 9, 2015 | Tax Foundation

    ... in 2014-take Burger King and Tim Hortons (Canada), Medtronic and Covidien (Ireland), and Endo International and Paladin Labs (Ireland) as examples-and the trend is continuing in 2015, with multiple big-name companies, such as Cyberonics and Wright ...

    Comment?

  7. Ariad And Paladin Labs Inc. Announce Commercial Distribution...Read the original story

    Jun 9, 2015 | BioSpace

    CAMBRIDGE, Mass., & MONTREAL-- --ARIAD Pharmaceuticals, Inc. and Paladin Labs Inc., an operating company of Endo International plc , today announced that ARIAD has granted Paladin exclusive rights to distribute Iclusiga in Canada for its newly approved indications. Paladin is focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market.

    Comment?

  8. ARIAD and Paladin Announce Commercial Distribution Agreement for...Read the original story w/Photo

    Jun 10, 2015 | Investor's Business Daily

    CAMBRIDGE, Mass., & MONTREAL-- -- ARIAD Pharmaceuticals, Inc. and Paladin Labs Inc., an operating company of Endo International plc , today announced that ARIAD has granted Paladin exclusive rights to distribute Iclusiga in Canada for its newly approved indications. Paladin is focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market.

    Comment?

  9. Endo To Purchase Par PharmaceuticalsRead the original story

    May 21, 2015 | Chemical and Engineering News

    ... spree for Endo. In early 2014, Endo moved its headquarters to Ireland through a tax inversion deal with Paladin Labs. Since then, it has bought three small companies but was thwarted in an $11 billion bid to buy Salix Pharmaceuticals when Valeant ...

    Comment?

  10. Endo To Purchase Par PharmaceuticalRead the original story w/Photo

    May 18, 2015 | Chemical and Engineering News

    ... In early 2014, Endo moved its headquarters to Ireland through a tax inversion deal in which it acquired Paladin Labs. Since then it has acquired two other smaller companies, but its most recent attempted $11 billion takeover of the gastrointestinal ...

    Comment?

  11. Endo Pharmaceuticals Posts A Solid Q1 Earnings ReportRead the original story

    May 12, 2015 | GuruFocus.com

    ... up newly posted sales of $73 million in the first quarter and this was majorly affected by product sales from Paladin Labs that was acquired in February last year. Recently, the company has announced to buy the branded and generic drug portfolio ...

    Comment?

  12. Knight Therapeutics: A solid long-term bet in the health care spaceRead the original story w/Photo

    May 5, 2015 | Globe and Mail

    Jonathan Ross Goodman, president and CEO of Knight Therapeutics. Knight's rich valuation isn't only about sector rotation into health care - it's a bet on Mr. Goodman, who is famous in investment circles for building Paladin Labs over almost two decades and then selling it to Endo Health Solutions for a total stock return of 9,000 per cent.

    Comment?

  13. Comings & Goings: News DigestRead the original story w/Photo

    May 3, 2015 | Wall Street Journal

    ... commercial landlord Brookfield Office Properties Inc. and Canadian companies such as True Gold Mining and Paladin Labs Inc. In a statement, Arnold & Porter Chairman Thomas H. Milch called Mr. Shepherd a "great fit," highlighting his "extensive ...

    Comment?

  14. FDA Pulls Approval for Dog Antifreeze AntidoteRead the original story w/Photo

    Apr 14, 2015 | Pet Product News

    The U.S. Food and Drug Administration withdrew approval for Antizol-Vet, an antidote for antifreeze poisoning in dogs available through veterinarians, at the request of the drug's sponsor, Paladin Labs Inc. Paladin Labs requested that the FDA withdraw the approval because the company has not manufactured or marketed the drug since Oct. 1, 2014. The most recent lot marketed in the U.S. is lot #1319-12A with an expiration date of August 2017.

    Comment?

  15. FDA Withdraws Antifreeze Antidote for Dogs ApprovalRead the original story w/Photo

    Apr 7, 2015 | Kansas City InfoZine

    ... approved by FDA in 1996, Antizol-Vet is an antidote for ethylene glycol (antifreeze) poisoning in dogs. Paladin Labs (USA) Inc., the current sponsor of Antizol-Vet, requested that the FDA withdraw the approval because the company has not ...

    Comment?

  16. SQI Diagnostics Appoints Chief Financial OfficerRead the original story

    Mar 3, 2015 | Sys-Con Media

    ... Directors, played an integral role in the development and execution of ConjuChem's IPO. Mr. Ryer also worked at Paladin Labs Inc., a specialty pharmaceutical firm, from 1999-2001, in the position of CFO and VP Finance. At Paladin, Mr. Ryer ...

    Comment?

  17. Exclusive - Drugmaker Endo vying for Salix takeover: sourceRead the original story

    Feb 13, 2015 | West Australian

    ... er Dava Pharmaceuticals for $600 million last June. A $1.6 billion acquisition of Canadian speciality drugmaker Paladin Labs last year allowed the company to relocate to Ireland, where corporate tax rates are lower, in a so-called inversion deal.

    Comment?

  18. Retiree's adventurous portfolio holds only stocksRead the original story w/Photo

    Feb 13, 2015 | The Globe and Mail

    ... too great a sacrifice in foreign diversification. His best move was adding 50 per cent to his holding of Paladin Labs Inc. three days before it doubled on a takeover offer (after enjoying a 50 per cent gain during the previous year). "One of my ...

    Comment?

  19. Looking For Opportunity In Endo's Structural ChangesRead the original story w/Photo

    Feb 5, 2015 | Seeking Alpha

    ... the main reasons why these changes will bring more value. The first acquisition to pay attention to is the Paladin Labs acquisition. Paladin Labs has a great portfolio of more than 60 generics which are in the market at the current moment. Paladin's ...

    Comment?

  20. Knight Therapeutics: Minimal Downside For This Misunderstood CompanyRead the original story w/Photo

    Dec 16, 2014 | Seeking Alpha

    Knight Therapeutics is a spin-off run by former Paladin Labs CEO, Jonathan Goodman, who grew Paladin's share price 100x over approximately 20 years. With Mr. Goodman's excellent track record, Knight has the potential to increase market value by many multiples over the next few years as it acquires and licenses various pharma products.

    Comment?